US Congress Investigates Psychiatric Drug Industry
Several different USA Congressional committees have been asked to investigate corruption, fraud and cover-up by the psychiatric drug industry.
- Top Psychiatrist Didn't Report Drug Makers' Pay
- NY Times continues coverage of congressional investigation led by Senator Charles E. Grassley (R-IA) exposing psychiatric drug company corruption, this time involving Dr. Charles B. Nemeroff of Emory University, who has resigned as chair of his department.
- "Psychiatric Group Faces Scrutiny Over Industry Ties"
- In this article, The New York Times covers the demand by Senator Charles E. Grassley (R-IA) that the APA become more transparent in its financing after numerous conflicts of interest were revealed.
- Sunday New York Times on Congressional investigation of Harvard psychiatrist
- US Senator Charles E. Grassley helped investigate corruption by the psychiatric drug industry. His investigation revealed that Harvard psychiatrist Dr. Joseph Biederman had illegally covered up much of more than a million dollars he had received from the psychiatric drug industry. Dr. Biederman is credited with helping to increase the number of young people diagnosed as "bipolar" many-fold.
- House Lawmaker Seeks Data From Makers of Stents and Drugs
- Congressman Henry Waxman (D-Calif.) is looking into allegations of inappropriate marketing of Zyprexa and other drugs and medical devices, according to Reuters. Waxman is the chairman of a house committee investigating off-label drug marketing by Eli Lilly & Company, AstraZeneca and Cephalon. Off-label use occurs when doctors prescribe products for unapproved purposes.
- Research Center Tied to Drug Company
- Further reports from The New York Times about how a Congressional investigation revealed that psychiatrist Dr. Joseph Biederman misused the name of his institution -- Harvard -- to fraudulently promote the massive use of the psychiatric drgus known as neuroleptics or antipsychotics.
- Expert or Shill?
- The New York Times editorial board weighs in on the corruption in the psychiatric industry exposed by recent USA Congressional investigations.
- No Mugs, but What About Those Fees
- The Sunday New York Times editorialized that the corruption exposed between the psychiatric profession and the drug industry must end.